Denali Therapeutics (DNLI) Profit After Tax (2017 - 2026)
Denali Therapeutics' (DNLI) quarterly Profit After Tax came in at -$129.8 million in Q1 2026, up 2.38% year-on-year from -$126.8 million in Q1 2025, and down 0.98% on a QoQ basis from -$128.5 million in Q4 2025.
Denali Therapeutics (DNLI) Profit After Tax (2017 - 2026) Analysis & Trends
Denali Therapeutics (DNLI) has 10 years of Profit After Tax data on file, last reported at -$129.8 million in Q1 2026.
- On a quarterly basis, Profit After Tax rose 2.38% year-over-year to -$129.8 million in Q1 2026; TTM through Mar 2026 was -$509.4 million, a 12.22% decrease from a year earlier, with the FY2025 full-year figure at -$512.5 million, down 21.63% from the prior year.
- Profit After Tax for Q1 2026 stood at -$129.8 million, down from -$128.5 million in the prior quarter.
- Over the last five years, Profit After Tax for DNLI reached as high as $183.4 million in Q2 2023 and fell as low as -$133.0 million in Q1 2025.
- Historically, Profit After Tax has averaged -$90.0 million across 5 years, with a median of -$107.2 million in 2024.
- Across the five-year window, Profit After Tax soared 396.65% in 2023 and tumbled 154.74% in 2024, its largest moves.
- Year by year, Profit After Tax stood at -$89.3 million in 2022, then slipped by 25.32% to -$111.9 million in 2023, then slipped by 1.28% to -$113.4 million in 2024, then slipped by 13.38% to -$128.5 million in 2025, then decreased by 0.98% to -$129.8 million in 2026.
- Per Business Quant data, the three most recent Profit After Tax figures were -$129.8 million in Q1 2026, -$128.5 million in Q4 2025, and -$126.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -36.84 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -65.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Denali Therapeutics | 4.37 Bn | 4.37 Bn | - | -129.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -129.81 Mn |
| Dec 31, 2025 | -128.55 Mn |
| Sep 30, 2025 | -126.90 Mn |
| Jun 30, 2025 | -124.12 Mn |
| Mar 31, 2025 | -132.97 Mn |
| Dec 31, 2024 | -113.38 Mn |
| Sep 30, 2024 | -107.19 Mn |
| Jun 30, 2024 | -100.39 Mn |
| Mar 31, 2024 | -103.74 Mn |
| Dec 31, 2023 | -111.94 Mn |
| Sep 30, 2023 | -98.56 Mn |
| Jun 30, 2023 | 183.38 Mn |
| Mar 31, 2023 | -109.78 Mn |
| Dec 31, 2022 | -89.32 Mn |
| Sep 30, 2022 | -102.88 Mn |
| Jun 30, 2022 | -61.82 Mn |
| Mar 31, 2022 | -71.97 Mn |
| Dec 31, 2021 | -75.26 Mn |
| Sep 30, 2021 | -84.59 Mn |
| Jun 30, 2021 | -60.83 Mn |